Clinical Trial Detail

NCT ID NCT04029688
Title A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

neuroblastoma

Advanced Solid Tumor

B-cell acute lymphoblastic leukemia

acute myeloid leukemia

Therapies

Idasanutlin + Venetoclax

Cyclophosphamide + Idasanutlin + Topotecan

Cytarabine + Fludarabine + Idasanutlin

Cytarabine + Hydrocortisone + Methotrexate

Cytarabine

Methotrexate

Idasanutlin

Cyclophosphamide + Idasanutlin

Age Groups: adult child

No variant requirements are available.